, and the evidence of its broad spectrum cytoprotective properties resulting in a reduction of both haematologic and organ toxicities without tumour protection (Kemp et al, 1996; Elias et al, 2000; Hartmann et al, 2000a Hartmann et al, , 2000b . Preservation of renal function using the combination of cisplatin, ifosfamide and etoposide plus amifostine had been previously demonstrated (Hartmann et al, 1999b) . Based on this background a randomized pilot study was conducted to evaluate the degree of side effects during HDCT and its possible prevention by amifostine in patients with solid tumours. In-patient costs for both treatment arms were compared in detail.
MATERIAL AND METHODS

Inclusion and exclusion criteria
Criteria for inclusion were required as follows: ECOG performance status of 0 or 1, adequate bone marrow function (WBC-count у 4000 µl Ϫ1 , platelet-count ≥ 100 000 µl Ϫ1 and granulocyte count ≥ 2000 µl Ϫ1 ), adequate renal (serum creatinine concentration ≤ 1.2 mg dl Ϫ1 and creatinine clearance ≥ 80 ml min Ϫ1 ) and liver function (bilirubin level ≤ 2.0 mg dl Ϫ1 , and AST and ALT ≤ 3 times normal). Parameters for ineligibility included presence of brain metastases, symptoms of ischaemic heart disease, and history of congestive heart failure or myocardial infarction within the immediate preceding 6 months and/or clinically significant arrhythmia.
Patients had given informed consent both for the treatment with HD-VIC and for the randomization to pretreatment with or without amifostine. Patients were stratified according to the absence or presence of prior chemotherapy. This study had been approved by the local University ethical committee.
Treatment schedule
All patients were randomized to receive HD-VIC chemotherapy plus PBSC transplant and granulocyte colony-stimulating factor (G-CSF) support either with or without amifostine pretreatment during HDCT as outlined in Table 1 . HDCT consisted of an simultaneous 18 h infusion of carboplatin 500 mg/m 2 /d and ifosfamide 4 g/m 2 /d preceded by a 4 h infusion of etoposide 500 mg/m 2 /d, all applied on three consecutive days (Fetscher et al, 1999) .
Antiemetic prophylaxis consisted of 5-HT 3 -antagonists and dexamethasone (20 mg i.v.) administrated 30 minutes prior to chemotherapy application. Dexamethasone 4 mg was repeated at 4 and 12 hours after the start of chemotherapy. Patients treated with amifostine additionally received 10 mg trifluorpromazine intravenously at each day of treatment. All patients received autologous PBSC transplantation two days after HDCT and G-CSF at a dose of 5 µg kg Ϫ1 body weight as a subcutaneously injection starting at day +5 until the granulocyte count was >5000 µl Ϫ1 (Table 1) . Patients were monitored for nephrotoxicity, gastrointestinal side effects, haematopoetic recovery, frequency of fever/infections, and days spent in hospital. All patients underwent daily blood counts, serum electrolytes and creatinine measurements and a careful clinical examination. Creatinine clearance was measured immediately before and at day 10 after the application of HDCT. Patients were stratified according to pretreatment (none versus ≥ 1 chemotherapeutic regimen/s) and the number of reinfused PBSC (<2.9 or ≥ 3.0 ϫ 10 6 CD34+ cells/kg body weight).
Supportive treatment
All patients received ofloxacin 200 mg orally twice daily and fluconazol 100 mg orally daily as antibacterial and antifungal prophylaxis starting at the day of treatment and continued unless intravenous antibiotic treatment was required in case of fever. Empiric combination treatment of a double-lactam penicilline and an aminoglycoside antibiotic was started when temperatures exceed 38.5˚C. The antibiotic regimen was modified according to microbiologic findings and clinical requirements. Patients were not nursed in reverse-barrier isolation. Total parenteral nutrition was given during periods of inadequate oral calorie intake. Following HD-VIC it was routine practice to transfuse red blood cell concentrates to maintain haemoglobin-levels higher than 8 g dl Ϫ1 and platelet concentrates to maintain platelet count ≥ 15 000 l Ϫ1.
Application of amifostine
Amifostine was applied at 910 mg/m 2 as a 15-min intravenous infusion completed 15 min before the start of the simultaneous carboplatin and ifosfamide infusion at each of the three consecutive days of treatment. Blood pressure was monitored every 5 min during the amifostine infusion. Amifostine was interrupted in case of a >20 mmHg decrease in systolic blood pressure depending on the patients baseline blood pressure level. Antihypertensive medication was withheld within 24 hours after amifostine administration.
Urine sample collection and measurement of urinary marker excretion
Urine samples were collected immediately prior to HDCT (dayϪ1) and on days 3, 5 and 10 after HDCT. Parameters of glomerular and tubular renal function such as total protein, albumine fraction, low molecular weight proteins (LMW), high molecular weight proteins (HMW), α 1 -microglobulin and N-acetyl-β 2 glucosaminidase (NAG) were determined from the urinary samples as described earlier (Hartmann et al, 2000b) . Ratios for creatinine clearance (C creatinine ) were calculated using the general clearance formula for a substance y: clearance y = ([urine] y /[plasma] y ) ϫ urine volume. 
Measurement of toxicity
Except for nephrotoxicity which was also characterized by the measurement of creatinine clearance and the degree of urinary protein excretion, side effects of treatment were classified according to WHO toxicity scale. In order to minimize observation bias the degree of toxicity of the gastrointestinal tract, such as nausea, vomiting, stomatitis and diarrhoea, was judged by the same person during the study period. For statistical calculation the highest toxicity degree occurring during HDCT was used to compare the both study arms.
Calculation of treatment costs
Detailed financial accounts of charges for each patient included into the study were reviewed from the beginning of chemotherapy until discharge. Charges were converted from German marks (DEM) to Euro (Euro 1 = DEM 1.95). The cost analysis was based on average wholesale price for each resource in Germany. Prices for alimentation and transfusions were obtained from the billing records of the University Medical Center Tübingen. The economic calculation was performed on the basis of direct medical costs (including drugs, costs of hospitalization, diagnostic radiology, labaratory tests, cultures, pharmacy, blood products) from a third party payer perspective from the start of treatment to discharge (Eisenberg, 1989; Russel et al, 1996) . However, the costs for nursing and professional time as well as monitoring devices associated with care for severely ill patients were not considered separately because these costs are included in the costs of hospitalization in the German health system. Indirect costs, f.e. decreased work productivity, or costs savings due to a different degree of late side effects were also not considered in the analysis. Patients were discharged in case of independence from platelet transfusions defined as a thrombocyte count >25 000 µl Ϫ1 on two consecutive days and recovery of neutrophil >1500 µl Ϫ1 , absence of fever and complete recovery from other grade III/IV toxicity.
Statistics
Non-parametric parameters of haematologic, renal, gastrointestinal toxicity as well as changes in the excretion rate of urinary analytes were compared using the Mann-Whitney U-Test. Statistical analysis was performed with SPSS 6.0 (SPSS, Chicago, IL, USA). Significance was defined as P≤ 0.05. All reported P values were two-sided. Friedman-Oneway-ANOVA procedures were applied in the follow-up of arms to evaluate whether the variance of the excretion rates of the urinary analytes was influenced by the time point of collection.
RESULTS
Patients' characteristics
40 consecutive patients receiving HD-VIC plus autologous PBSC transplantation for different solid tumours between August 1997 and January 1999 were enrolled into the study and were followed from start of treatment until discharge. Patients' characteristics are listed in Table 2 . Patients in both arms were comparable in terms of pretreatment due to stratification. Of 40 patients randomized either to the amifostine arm or to the control arm, 26 (65%) had received no previous chemotherapy except for two cycles of induction chemotherapy (VIP-regimen consisting of etoposide, ifosfamide, cisplatin) to collect PBSC before the application of the HD-VIC therapy examined here (Fetscher et al, 1999) . While 6 patients in the amifostine arm had previously treated with chemotherapy regimens containing cisplatin or ifosfamide, none of the patients belonging to the control arm had received these types of chemotherapy. The majority of patients had metastatic breast cancer and had been treated with HDCT according to the GEPDIS protocol (German Breast Cancer Dose Intensity Study).
Nephrotoxicity
All 40 patients were evaluable for serum creatinine, creatinine clearance (GFR = glomerular filtration rate) and magnesium values, and for urinary marker excretion analysis. Both arms had received a comparable volume load of either saline or saline plus glucose solution, as well as a comparable use of diuretics. No differences existed in baseline parameters (day -1) between both arms (P > 0.05) except for the magnesium serum and creatinine serum concentrations both in favour of the control group (P = 0.02 and P = 0.02). Patients treated with HD-VIC plus amifostine revealed a significantly lower degree of renal damage compared to the control arm. Following HDCT the median GFR values decreased by 37% from 107 ml min Ϫ1 (63-196) at baseline to 67 ml min Ϫ1 (30-148) at day 10 in control patients. In contrast, in the amifostine arm the GFR was almost completely preserved with 102 ml min Ϫ1 (60-149) prior to and 92 ml min Ϫ1 (51-133) after application of chemotherapy (P < 0.01). 60% of patients treated with HD-VIC alone had a GFR < 60 ml min Ϫ1 at day 10 after treatment compared to 20% of patients in the amifostine arm (Table 3) .
The median decrease of serum magnesium levels was 8% in patients with HD-VIC plus amifostine versus 17% in patients without amifostine. However, the nadirs of Mg values were comparable due to different serum concentrations prior to the start of chemotherapy between both treatment arms. Magnesium levels have completely recovered in both groups at day 10 after treatment.
The determination of urinary markers revealed significant nephrotoxic effects in both treatment arms. Protein excretion for all fractions was increased about 20 to 35-fold by days 3 and 5 in both arms. There were no signs of any pre-or post-renal causes for these changes, such as e.g. haemorrhagic cystitis. An electrophoretic separation of the proteins excreted showed that the excretion of all three protein fractions, HMW proteins, albumin and LMW proteins, was significantly elevated following HDCT, as well as α 1 -microglobulin and NAG as markers of a proximal tubular damage. The excretion of LMW proteins at day 3 and albumine at days 3,5,10 was significantly lower in the amifostine arm compared to control patients (P < 0.05) ( Table 4) .
Haematotoxicity
All patients experienced WHO grade IV haematotoxicity followed by a full haematologic reconstitution. Granulocyte counts > 500 µl after PBSC-transplantation were observed at day 9 (range, 7-12) in the amifostine arm and at day 10 (range, 8-13) in the control All values given in median and standard deviation. a = Mann-Whitney U-test. pts = patients. GFR = creatinine clearance in ml/min (baseline to day 10).
b After HDCT. arm (P = 0.02). Both arms have received additional treatment with G-CSF s.c. Thrombocyte engraftment (> 25 000 µl Ϫ1 ) was reached at a median of two days earlier in the amifostine arm (P = 0.01). However, patients in both groups needed platelet transfusions after HD-VIC. The number of reinfused PBSC was comparable for both arms (2.8 (range, 2.0-3.9) versus 3.0 ϫ 10 6 CD34+ cells µl
Ϫ1
(range, 2.2-7.8); P = 0.3). The median number of days with fever > 38.5˚C was 2 (range, 0-5) in amifostine pretreated patients versus 4 days (range, 0-7) in control patients (P = 0.03) ( Table 5) .
Gastrointestinal toxicity
All patients had routinely received 5-HT 3 -receptor antagonists and dexamethasone as antiemetic prophylaxis. Patients treated with amifostine additionally received 10 mg trifluorpromazine intravenously at each day of treatment (days 1-3). Some degree of acute nausea shortly after or during the application of amifostine was observed in all patients (see side effects of amifostine). However, the proportion of patients with delayed nausea/vomiting (defined as beyond 24 hours after completion of chemotherapy) grade ≤ III was higher in the control arm resulting in a overall lower rate of antiemetics applied. Both stomatitis and diarrhoea WHO grade III/IV was observed in 25% of patients with amifostine and in half of the patients without amifostine (Table 6) . Side effects associated with the use of amifostine were acute short-lasting nausea/vomiting observed after or during the administration of amifostine, a mild self-limited rash (20/20 cycles = 100%), sneezing (30%), hypotension (= blood pressure decrease > 20 mmHg) without requiring medical intervention (25%), hiccups (15%) and mydriasis (5%). Mild and asymptomatic hypocalcaemia was observed in 80% of patients (n = 12/15 evaluable) in the amifostine and 73% of patients in the control arm (n = 11/15 evaluable). The mean decrease of serum magnesium was 16% (range, 9-26%) in the amifostine arm at day 4 (range, 3-10) and 13% (range, 4-24%) in the control patients at day 7 (range, 3-13). All patients had routinely received intravenous calcium supplementation during treatment (see Table 1 ). There was no treatmentrelated mortality observed in both arms.
In-patient cost calculation
Pretreatment with amifostine resulted in a reduced use of antibiotics, diagnostic radiology and cultures, platelet and red blood cell transfusions, as well as of parenteral nutrition compared to control patients. Despite a higher rate of acute nausea and emesis observed immediately during or after the infusion of amifostine, an increased frequency of delayed nausea and vomiting resulted in higher costs for antiemetic medication in the control arm as stated before. Patients treated with amifostine were discharged from hospital at day 16 compared to day 18 in the control arm (P < 0.01). Therefore, costs for laboratory and hospitalization were lower.
Overall costs for supportive care were Euro 63 063 (Euro 3153 per patient) in the amifostine arm versus Euro 87 931 (Euro 4396 per patient) in the control arm (not considering the additional costs of the drug amifostine). Thus, savings of supportive care costs in the amifostine arm were Euro 1243 per patient. Taking into account the drug costs of amifostine (Euro 1783 per patient), treatment with amifostine resulted in additional costs of Euro 540 per patient compared to the control arm (Table 7) .
DISCUSSION
High-dose chemotherapy (HDCT) with autologous peripheral blood stem cell transplantation has been used for defined subgroups of patients with chemosensitive malignancies. The escalation of drugs such as etoposide and ifosfamide and the use of high-dose carboplatin has become possible through the management of haematotoxicity with the availability of recombinant haematopoietic growths factors and PBSC techniques. However, with increased dosages of cytostatics non-haematologic organ toxicities have become dose-limiting. Patients treated with regimens like HD-ICE/-VIC/-CEI containing carboplatin, ifosfamide and etoposide are at risk for pronounced gastrointestinal toxicity, infections, acute CNS toxicity and cognitive impairment (Siegert et al, 1994; Elias et al, 1995; Wright et al, 1995; Beyer et al, 1997; van Dam et al, 1998; Fetscher et al, 1999) . Additionally, high dose carboplatin, which is not nephrotoxic when applied in standard doses and high-dose ifosfamide can produce significant renal damage (Hartmann et al, 2000c; Wagstaff et al, 1989; van Dam et al, 1998) . The level of side effects may be pronounced particularly in patients who have undergone intensive pretreatment. Thus, it is important to evaluate methods to reduce these toxicities for regimens commonly used in the HDCT setting.
In clinical practice nephrotoxicity is measured via creatinine serum values and the determination of the glomerular filtration rate (GFR). The GFR measured by creatinine clearance is a more sensitive parameter to detect glomerular damage compared to serum creatinine values. In this study the GFR was clearly affected in patients receiving HD-VIC without prior application of amifostine. Patients in the control arm had a median loss of GFR of 37% compared to their baseline level after the application of the HDCT cycle, and 35% of these patients had GFR values below 60 ml min -1 at day 10 after HDCT. This reduction of GFR may result in clinically relevant long-term effects particularly when further therapy is required in the case of relapse, or when a second cycle of HDCT is planned, or even when other nephrotoxic agents such as aminoglycoside antibiotics have to be used. Among patients receiving amifostine during HD-VIC chemotherapy the GFR value dropped only by a median of 10% and no patient developed GFR-values below 60 ml min Ϫ1 at day 10. Nephroprotection was also demonstrated by a lower degree of urinary protein excretion-particularly LMW proteins and albumine-compared to patients in the control group. Magnesium and calcium supplementation were used during the hydration period in both treatment arms, and therefore hypomagnesaemia or symptomatic hypocalcaemia were not a clinically evident problem in both groups (Wadler et al, 1993) . Although hypocalcaemia was observed earlier in the time course after the application of treatment in amifostine-pretreated patients (day 4 versus 7), the degree and frequency were comparable among both arms.
The degree of nephrotoxicity in the HDCT setting with regimen based on ifosfamide and high-dose carboplatin was not unexpected (Rosti et al, 1992; Barnett et al, 1993; Siegert et al, 1994; Fields et al, 1995; Margolin et al, 1996; Fetscher et al, 1999) . Broun and coworkers (1991) have observed renal failure in 4 of 7 patients and gross haematuria in 2 patients. Siegert et al (1994) reported a somewhat lower level of nephrotoxicity. This discrepancy may be explained by the different duration of ifosfamide application. In the first trial (Broun et al, 1991) the drug was applied as a short infusion over 30 minutes, whereas in the study of Siegert et al (1994) it was administrated as continuous infusion over 22 hours, thus avoiding high peak drug concentrations.
In an analysis of 150 consecutively treated patients with relapsed germ cell tumours treated with HD-CEI (carboplatin 1500-2000 mg/m 2 /etoposide, 1200-2400 mg/m 2 /ifosfamide 0-10 g/m 2 ) followed by either bone marrow or PBSC rescue, mortality was 3% (n = 5 patients), with 3 patients dying from severe renal toxicity (Beyer et al, 1997) . Overall, acute nephrotoxicity occurred in 29% of patients, particularly at carboplatin >1500 mg/m 2 . Nephrotoxicity was defined as either a decline in the estimated creatinine clearance of ≥50% or as an absolute increase of serum creatinine ≥1 mg dl Ϫ1 . Intermittent haemodialysis was required in 8% of patients, and two patients entered chronic haemodialysis. Nephrotoxicity resulted in an increased needs for transfusions, more overall toxicity and a prolonged hospital stay. Whereas the intensity of previous exposure to cisplatin has been reported as a risk factor for nephrotoxicity from ifosfamide administration in children (Goren et al, 1987) , Beyer and coworkers were unable to identify any variables that might predict acute nephrotoxicity after HD-CEI treatment. Two other reports that studied HD-CEI in heterogeneous patient populations described the frequency of acute nephrotoxicity as 46% and 29%, respectively (Wilson et al, 1992; Elias et al, 1995) . Empiric dose reduction of HD-CEI has been suggested as soon as the deterioration of renal function becomes apparent in order to prevent further renal damage. The strategy of empiring dose reductions is important and may save patients from irreversible side effects or even death, but, it did not prevent the occurrence of acute nephrotoxicity in about one third of patients. As an alternative method the a priori adjustment of the carboplatin dose according to the patients' renal function has been used to achieve a predefined target area under the curve for this drug (Calvert et al, 1989) . However, the formula that was devised by Calvert et al has only been established for singledosing and single-agent carboplatin administration. It does not take into account the day to day changes that occur with combination chemotherapy including further potentially nephrotoxic drugs and with repetitive dosing. In addition, no GFR-based formula for dose calculations of etoposide and ifosfamide exists.
Renal insufficiency was also the dose-limiting toxicity of the escalation of the HD-ICE regimen (Wright et al, 1995) . Wright and coworkers proposed a model of plasma drug level measurement early during treatment to provide warning of renal failure. 9 patients received a 96 h infusion of ifosfamide (16 g/m 2 ), carboplatin (1.6 g/m 2 ) and etoposide (1.2 g/m 2 ). The drug levels and plasma concentration-time curves of ifosfamide, ultrafiltrable platinum and etoposide were analysed and correlated with renal function. One of the 9 patients developed anuric renal failure requiring haemodialysis. The authors conclude that high plasma ifosfamide and ultrafiltrable platinum levels analysed early in the course of the 96 h infusion of HD-ICE may provide a warning of severe and potentially fatal renal injury.
Stomatitis with oesophagitis was common with HD-VIC . Fields et al (1995) reported a high incidence of enteritis, renal failure and veno-occlusive disease, as well as a 9% mortality. Siegert et al reported that at doses of carboplatin 1.5 g/m 2 , etoposide 2.4 g/m 2 and ifosfamide 10 g/m 2 (HD-CEI) WHO grade III/IV haematotoxicity occurred in 100%, nausea in 100% and diarrhoea in 30% and hepatotoxicity in 10% of patients. All patients developed granulocytopenic fever. 3% of patients died of treatment-related complications.
In our pilot study amifostine has also shown to significantly ameloriate the gastrointestinal side effects of HD-VIC chemotherapy such as stomatitis, delayed nausea and vomiting, and severe diarrhoea/enteritis. Acute nausea shortly after or during the application of amifostine was a manageable therapeutic problem with trifluorpromazine added prophylactically to a 5-HT 3 -receptor antagonists plus dexamethasone. The reduced rate of delayed nausea/vomiting and less stomatitis in the amifostine arm even resulted in a lower rate of subsequently applied antiemetic medications and parenteral nutritions.
Amifostine has previously been demonstrated to reduce chemotherapy-induced neutropenia and cumulative bone marrow toxicity of treatment with carboplatin, cyclophosphamide and cisplatin (Glover et al, 1986; Treskes et al, 1993; Budd et al, 1999 ). In the current series with prophylactic application of G-CSF granulocyte engraftment occurred nearly at the same time in both treatment arms. Thrombocyte engraftment was observed earlier in the amifostine arm compared to controls. The number of reinfused PBSC was comparable between both arms excluding a possible source of bias in this analysis. Even this moderately faster haematopoietic recovery in the amifostine arm was associated with a fewer number of days with fever > 38.5˚C and a lower requirement of i.v. antibiotics.
The calculation of treatment costs has become important in the oncological setting, particularly when introducing drugs for supportive care (Bennett et al, 1994 (Bennett et al, , 1999 Glasziou and Mitchell, 1996; Fayers and Hand, 1999) . Aspects of quality of life and economics are nowadays established separate endpoints in cancer trials. Agents that may result in acute and/or long-term benefits should thus be evaluated in detail. We have provided a clinical economic estimate of direct treatment costs during the in-patient period in the HDCT-setting from a third party payer view. It was not possible to consider treatment costs for possible long-term toxicities and indirect non-medical costs in this analysis. The reduction of HDCT-related acute toxicities by amifostine resulted in lower costs for supportive care medication and an earlier discharge of patients from the hospital. Savings of supportive care costs in the amifostine arm were Euro 1243 per patient. Taking into account the drug costs of amifostine (Euro 1783 per patient), treatment with amifostine resulted in incremental costs of Euro 540 per patient. Similar to the use of G-CSF in adult patients with acute myelogenous leukaemia with in-patient costs savings of US $2300 (Bennett et al, 1999) , previous pharmaeconomic reports have indicated that amifostine has a favourable clinical and cost-utility profile in the treatment of advanced ovarian cancer compared to other medical therapies such as autologous bone marrow transplantation for relapsed Hodgkin's disease or acute non-lymphocytic leukaemia or adjuvant tamoxifen in premenopausal oestrogen receptor-negative women (Detsky and Naglie, 1990) .
In summary, the results from this randomized pilot study indicate that amifostine can ameloriate the acute side effects of HD-VIC chemotherapy with overall additional costs of approximately Euro 550 per patient. Thus, a larger prospective trial needs to address the definitive degree at which amifostine may increase the safety of the widely used HDCT regimens based on carboplatin, etoposide and ifosfamide and possibly other HDCT regimens. Whether the reduction of the level of acute toxicity is transferred into a lower degree of long-term toxicity and further costs savings has to be determined in consecutive trials.
